Ingrezza Emerging Drug Insight

“Ingrezza Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Ingrezza for Huntington’s disease and schizophrenia in the 7MM. A detailed picture of the Ingrezza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Ingrezza. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Ingrezza market forecast, analysis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies.

Drug Summary

Neurocrine Biosciences is currently developing valbenazine, also known as Ingrezza, an investigational treatment for chorea associated with Huntington’s disease and schizophrenia. It is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, believed to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function. A protein in the brain termed VMAT2 packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. Ingrezza is a novel molecule that selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Ingrezza description, mechanism of action, dosage and administration, research and development activities in Huntington’s disease and schizophrenia.
• Elaborated details on Ingrezza regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Ingrezza research and development activity in Huntington’s disease and schizophrenia in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Ingrezza (Deutetrabenazine).
• The report contains forecasted sales of Ingrezza for Huntington’s disease and schizophrenia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Huntington’s disease and schizophrenia.
• The report also features the SWOT analysis with analyst views for Ingrezza in Huntington’s disease and schizophrenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ingrezza Analytical Perspective by DelveInsight

• In-depth Ingrezza Market Assessment

This report provides a detailed market assessment of Ingrezza in Huntington’s disease and schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Ingrezza Clinical Assessment

The report provides the clinical trials information of Ingrezza in Huntington’s disease and schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Huntington’s disease and schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Ingrezza dominance.
• Other emerging products for Huntington’s disease and schizophrenia are expected to give tough market competition to Ingrezza and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Ingrezza in Huntington’s disease and schizophrenia.
• Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Ingrezza in Huntington’s disease and schizophrenia.

Key Questions

• What is the product type, route of administration and mechanism of action of Ingrezza?
• What is the clinical trial status of the study related to Ingrezza in Huntington’s disease and schizophrenia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Ingrezza development?
• What are the key designations that have been granted to Ingrezza for Huntington’s disease and schizophrenia?
• What is the forecasted market scenario of Ingrezza for Huntington’s disease and schizophrenia?
• What are the forecasted sales of Ingrezza in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Huntington’s disease and schizophrenia and how are they giving competition to Ingrezza for Huntington’s disease and schizophrenia?
• Which are the late-stage emerging therapies under development for the treatment of Huntington’s disease and schizophrenia?